Hemostemix Closes Private Placement of $461,230

Core Viewpoint - Hemostemix Inc. has successfully closed the first tranche of a non-brokered private placement, raising $461,230 through the issuance of 4,193,000 units at a price of $0.11 per unit, aimed at supporting its autologous stem cell therapy, VesCell™ [1][5] Group 1: Offering Details - The offering consists of units that include one common share and one common share purchase warrant, with each warrant allowing the purchase of an additional common share at $0.15 for two years [2] - The company paid approximately $23,698.40 in cash finder's fees and issued 215,440 finder's options, each allowing the purchase of one common share at $0.15 for 24 months [4] - The offering is subject to regulatory approvals and all securities issued will have a four-month hold period under Canadian securities laws [7] Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for general working capital and to support ongoing operations, particularly the marketing and sales of VesCell™ [5] Group 3: Company Background - Hemostemix is a leader in autologous stem cell therapy, having developed and patented VesCell™ (ACP-01), and has completed seven clinical studies with 318 subjects [8] - The company has reported significant clinical outcomes, including a 0% mortality rate in a specific patient population compared to a 50% five-year mortality rate, and an 83% wound healing rate in patients followed for up to 4.5 years [8]